Alzamend Neuro reports AL001 meets bioequivalence in phase II trial

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/9/2026

1. AAPL
2. SPY
3. NUVL
4. RBRK
5. APLD
6. GOOGL
7. SPCX
8. USO
9. CPB
10. AWK

Go back to Alzamend Neuro reports AL001 meets bioequivalence in phase II trial
(NASDAQ: ALZN) Delayed: 1.15 -0.01 (0.86%)
Previous Close $1.16    52 Week High $ 
Open $1.15    52 Week Low $ 
Day High $1.16    P/E N/A 
Day Low $1.12    EPS $ 
Volume 23,513